Cemiplimab Still Safe and Effective for cSCC, Study Shares
https://pixabay.com/en/vials-science-liquids-ionic-1781316/

Cemiplimab Still Safe and Effective for cSCC, Study Shares

  So far, the Phase 2 EMPOWER-CSCC-1 clinical study has evaluated cemiplimab (also known as Libtayo) in individuals with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). Data from…

Continue Reading Cemiplimab Still Safe and Effective for cSCC, Study Shares